tiprankstipranks
National Healthcare Properties (HLTC)
OTHER OTC:HLTC
US Market

National Healthcare Properties (HLTC) AI Stock Analysis

28 Followers

Top Page

HLTC

National Healthcare Properties

(OTC:HLTC)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 5.2)
Rating:45Neutral
Price Target:
$8.00
▲(8.11% Upside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance—persistent losses, unstable cash generation, and a major 2025 revenue disruption signal—despite improved leverage. Technicals are neutral-to-weak with modest negative momentum, and valuation is constrained by losses (negative P/E) with no dividend support provided.
Positive Factors
Improved leverage after large debt reduction
The large 2025 debt reduction materially lowers leverage and refinancing risk, improving financial flexibility. Over the medium term this should reduce interest burden and give management more optionality for asset repositioning, liability management or strategic transactions.
Negative Factors
Persistent multi-year net losses and negative ROE
Sustained net losses and consistently negative ROE undermine internal capital formation and limit the company's ability to fund maintenance, growth or distributions from operations. Over months this constrains strategic flexibility and raises questions about long-term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage after large debt reduction
The large 2025 debt reduction materially lowers leverage and refinancing risk, improving financial flexibility. Over the medium term this should reduce interest burden and give management more optionality for asset repositioning, liability management or strategic transactions.
Read all positive factors

National Healthcare Properties (HLTC) vs. SPDR S&P 500 ETF (SPY)

National Healthcare Properties Business Overview & Revenue Model

Company Description
Healthcare Trust, Inc. is a publicly registered real estate investment trust focused on acquiring a diversified portfolio of healthcare real estate, with an emphasis on seniors housing and medical office buildings, located in the United States....

National Healthcare Properties Financial Statement Overview

Summary
Despite a sharply improved balance sheet in 2025 from a large debt reduction, overall fundamentals remain pressured by persistent multi-year net losses, mostly negative free cash flow, and highly volatile operating cash flow. The 2025 revenue collapsing to $0 with negative gross profit is a major earnings-quality and continuity red flag that outweighs the leverage improvement.
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
26
Negative
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue0.00353.79M345.93M335.85M329.36M
Gross Profit-218.90M132.65M128.13M122.40M123.54M
EBITDA82.02M-22.36M76.87M53.76M42.59M
Net Income-71.07M-189.70M-72.30M-79.62M-85.18M
Balance Sheet
Total Assets1.71B1.95B2.15B2.18B2.21B
Cash, Cash Equivalents and Short-Term Investments57.62M21.65M46.41M53.65M59.74M
Total Debt380.95M1.15B1.18B1.12B1.09B
Total Liabilities1.11B1.26B1.24B1.18B1.17B
Stockholders Equity600.06M684.56M894.15M992.64M1.03B
Cash Flow
Free Cash Flow-21.77M-101.75M-773.00K302.00K19.81M
Operating Cash Flow6.95M-79.85M21.62M28.30M38.88M
Investing Cash Flow69.81M63.97M-62.82M-41.78M-47.92M
Financing Cash Flow-42.40M-1.35M55.97M4.64M4.08M

National Healthcare Properties Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.40
Price Trends
50DMA
7.64
Positive
100DMA
7.64
Positive
200DMA
7.80
Positive
Market Momentum
MACD
0.08
Negative
RSI
58.19
Neutral
STOCH
85.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLTC, the sentiment is Positive. The current price of 7.4 is below the 20-day moving average (MA) of 7.64, below the 50-day MA of 7.64, and below the 200-day MA of 7.80, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 58.19 is Neutral, neither overbought nor oversold. The STOCH value of 85.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HLTC.

National Healthcare Properties Risk Analysis

National Healthcare Properties disclosed 85 risk factors in its most recent earnings report. National Healthcare Properties reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

National Healthcare Properties Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$485.72M86.441.16%12.08%3.40%-240.85%
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
64
Neutral
$595.22M30.7810.87%7.51%0.68%-1.34%
64
Neutral
$176.86M21.5249.30%4.62%29.76%22.76%
54
Neutral
$1.77B-4.08-15.98%0.80%4.10%8.96%
45
Neutral
$227.30M-3.27-11.41%-2.72%69.06%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HLTC
National Healthcare Properties
8.00
-0.30
-3.61%
DHC
Diversified Healthcare Trust
7.29
5.24
256.30%
CHCT
Community Healthcare
17.00
3.73
28.13%
UHT
Universal Health Realty Income
42.90
8.25
23.80%
STRW
Strawberry Fields REIT Inc
13.22
3.05
30.03%

National Healthcare Properties Corporate Events

Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
National Healthcare Properties Accelerates Governance Reforms, Adds Director
Positive
Jan 12, 2026
On January 9, 2026, National Healthcare Properties, Inc. implemented a series of governance and structural changes, including amending its rights agreement to accelerate the expiration of its common share purchase rights to January 12, 2026, after...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 24, 2026